SENTINEL1: An Observational Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis-Reference-Cited by-同舟云学术

SENTINEL1: An Observational Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis

Published:2016-05-27 Issue:01 Volume:34 Page:51-61
ISSN:0735-1631
Container-title:American Journal of Perinatology
language:en
Short-container-title:Amer J Perinatol

Author:

Anderson Evan¹,Krilov Leonard²,DeVincenzo John³,Checchia Paul⁴,Halasa Natasha⁵,Simões Eric⁶,Domachowske Joseph⁷,Forbes Michael⁸,Pannaraj Pia⁹,McBride Scott¹⁰,McLaurin Kimmie¹¹,Ambrose Christopher¹¹,Kumar Veena¹¹

Affiliation:

1. Departments of Pediatrics and Medicine, Emory University School of Medicine, Atlanta, Georgia

2. Department of Pediatrics, Winthrop University Hospital, Mineola, New York

3. Department of Pediatrics, CFRI at Le Bonheur Children's Hospital, University of Tennessee Center for Health Sciences, Memphis, Tennessee

4. Department of Pediatrics, Texas Children's Hospital, Houston, Texas

5. Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee

6. Department of Pediatrics, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado

7. Department of Pediatrics, SUNY Upstate Medical University, Syracuse, New York

8. Department of Pediatrics, Akron Children's Hospital, Akron, Ohio

9. Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, California

10. Department of Statistics, United BioSource Corporation, Ann Arbor, Michigan

11. Department of U.S. Medical Affairs, AstraZeneca, Gaithersburg, Maryland

Publisher

Georg Thieme Verlag KG

Subject

Obstetrics and Gynaecology,Pediatrics, Perinatology, and Child Health

Link

http://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0036-1584147.pdf

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Differential anti-viral response to respiratory syncytial virus A in preterm and term infants;eBioMedicine;2024-04

2. Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study;The Lancet Regional Health - Americas;2023-12

3. Cost-effectiveness of nirsevimab and palivizumab for respiratory syncytial virus prophylaxis in preterm infants 29–34 6/7 weeks' gestation in the United States;Pediatrics & Neonatology;2023-09

4. Impact of prematurity on long-stay paediatric intensive care unit admissions in England 2008-2018;BMC Pediatrics;2023-08-24

5. Cost-Effectiveness Analysis of Nirsevimab and RSVpreF Vaccine Prevention Strategies for Respiratory Syncytial Virus Disease in infants: A Canadian Immunisation Research Network (CIRN) Study;2023-07-16